Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide add-on therapy in biopsy-proven diabetic nephropathy
ChiCTR2000036503Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Oct 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Urinary albumin-creatinine ratio. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000036503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036503.